I posted about this change way back in May. I was surprised At the time that we weren’t taking 65+ I knew that was a major and majority group of severe criticals we were leaving out. I’m not sure why 65+ were left out on trial design. We are already 2-1 leronlimab vs placebo but my guess is that they were trying to avoid the un-Savable that had so many underlying conditions that leronlimab wouldn’t save them even though it may reduce viral load to close times zero like we saw in the Montifier first 11 patients. I would be very interested to see the difference in mortality Pre May 4th and post May 4th